Clinical trials
Relapsed or Refractory Plasma Cell Neoplasms clinical trials
Below are recruiting relapsed or refractory plasma cell neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,685 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT04794777RecruitingPhase 3
Tests targeted scans and rescue radiation for returning prostate cancer
This trial studies whether a targeted scan (PSMA PET/CT) can help doctors choose the best “salvage” radiation treatment when prostate cancer comes back by PSA blood tests after surgery. It may help some people avoid under- or over-treating the areas where the cancer is returning.
Gothenburg, GöteborgAges 18 years+ - NCT04806464RecruitingPhase 1
Study drug injection for advanced liver cancer
This Phase 1 trial tests VG161, a study medicine, given by injection into liver or nearby tumors for people with advanced primary liver cancer that has not responded to standard treatment (or there is no standard option). The goal is to find a safe dose and see how the tumors respond.
Hangzhou, ZhejiangAges 18–75 - NCT04807881RecruitingPhase 1
Study of keynatinib for certain hard-to-treat lymphomas
This Phase 1 trial tests keynatinib, a new medicine, in people with specific types of lymphoma that have returned or not responded to earlier treatment. It aims to find a safe dose and see whether it can shrink tumors in the brain or elsewhere in the body, depending on the group.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04844866RecruitingPhase 2
CAR T-cell treatment versus standard care for relapsed lymphoma
This trial tests a CAR T-cell therapy (MB-CART2019.1) against standard treatment in people with certain types of aggressive B-cell lymphoma that has come back or didn’t respond to the first treatment. It aims to improve how well the lymphoma responds and to check for side effects and safety.
GrazAges 18–70 - NCT04857164RecruitingPhase 2
Pembrolizumab plus chemotherapy for recurrent or metastatic throat cancer
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04924868RecruitingPhase 3
Ursodeoxycholic acid to prevent gallstone pancreatitis returning
This trial tests whether ursodeoxycholic acid (a bile medicine) can help prevent complications from gallstone-related acute pancreatitis from coming back after you leave the hospital. It may help reduce repeat problems linked to gallstones, especially after an initial pancreatitis episode.
Santiago de Compostela, A coruñaAges 18 years+ - NCT04925609RecruitingPhase 1/Phase 2
Brigatinib for young people with ALK-positive cancer
This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.
ParisAges 1–25 - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
Los Angeles, CaliforniaAges 1–21 - NCT04959175RecruitingPhase 1/Phase 2
Lower post-transplant drug doses for older or unfit patients
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Bethesda, MarylandAges 12–85 - NCT04972760RecruitingPhase 3
Baricitinib for active dermatomyositis in adults
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
ParisAges 18–64 - NCT04990102RecruitingPhase 1/Phase 2
Trial drug to help prevent relapse in AML
This trial tests CPX-351 to help stop acute myeloid leukemia (AML) from coming back after you’ve reached remission. It’s for people who are not able to receive a stem cell transplant and need a new way to reduce relapse risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04996121RecruitingPhase 1/Phase 2
Drug for tumors with NTRK or ROS1 gene fusions
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05000801Recruiting
DC-AML cells for AML after remission but with relapse risk
This study tests DC-AML immune cells to help people with acute myeloid leukemia (AML) who are in remission but still show signs of leftover cancer cells or relapse risk. It may help the immune system attack AML cells, especially when a stem cell transplant is not an option.
Beijing, Beijing MunicipalityAges 18–70 - NCT05011266RecruitingPhase 2/Phase 3
Buprenorphine plus naltrexone shot to prevent opioid relapse
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
Rockville, MarylandAges 18–65 - NCT05019703RecruitingPhase 2
Atezolizumab plus cabozantinib for teen osteosarcoma
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
Boston, MassachusettsAges 12 years+ - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT05029791Recruiting
Study of immune markers in treated metastatic melanoma
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
LyonAges 18 years+ - NCT05041140Recruiting
Xenon MRI test for lung problems after stem cell transplant
This study uses a special MRI test with xenon gas to look at lung function in adults who had a stem cell transplant and now have breathing-related complications. It may help doctors measure lung impairment more clearly and track changes over time.
Houston, TexasAges 18 years+ - NCT05080556RecruitingPhase 2
Adaptive chemotherapy for ovarian cancer after platinum and PARP
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
LondonAges 18 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05097625Recruiting
Testing early detection of head and neck cancer relapse
This study aims to find signs of head and neck cancer coming back early, using scans/tests after you’ve had radical treatment. If you’re at higher risk and HPV-negative, this may help doctors catch relapse sooner.
LondonAges 18 years+ - NCT05101551RecruitingPhase 1
Talazoparib with chemotherapy for relapsed childhood AML
This Phase 1 study tests whether talazoparib combined with chemotherapy is safe and potentially effective for children and young adults whose leukemia has come back or did not respond. It focuses on finding the best way to give the treatment and watching for side effects.
Phoenix, ArizonaAges Up to 21 years - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Duarte, CaliforniaAges 18 years+
Hear when a new Relapsed or Refractory Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory plasma cell neoplasms?
- Yes. Clin2 currently lists 1,685 recruiting relapsed or refractory plasma cell neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory plasma cell neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory plasma cell neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
- Refractory Plasma Cell Myeloma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Multiple Myeloma and Malignant Plasma Cell Neoplasms
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.